跳至主要内容
临床试验/NCT02562703
NCT02562703Unknown1 期

Transcutaneous Vagus Nerve Stimulation for Treating Major Depressive Disorder: a Phase II, Randomized, Double-blind Clinical Trial

Santa Casa Medical School0 个研究点目标入组 40 人开始时间: 2015年11月1日最近更新:
适应症

试验速览

阶段
1 期
发起方
入组人数
40
主要终点
• Hamilton Depressive Rating Scale version 17 items (HDRS-17)

研究概览

简要总结

This is a phase II, randomized, sham controlled, clinical trial. This clinical trial has as primary objective to evaluate changes in depressive symptoms of a transcutaneous Vagus Nerve Stimulation (tVNS) treatment protocol for patients with moderate / severe depressive episode.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 59 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • patients between 18 and 69 years
  • patients with a diagnosis of depression according to the SCID
  • score greater than or equal to 18 on the Hamilton Rating Scale 17-item version (equivalent to moderate or severe depressive episode)
  • agreement to participate in the study as recommended in the IC.

排除标准

  • patients with psychiatric indication for hospitalization
  • patients with psychiatric comorbidity
  • patients with a diagnosis of personality disorder
  • presence of severe neurological or medical diseases such as neoplasms in activity, neurodegenerative diseases and chronic diseases uncompensated.

结局指标

主要结局

• Hamilton Depressive Rating Scale version 17 items (HDRS-17)

时间窗: Change from baseline in depressive symptoms at 2 weeks

This clinical trial has as primary objective to evaluate the effect of the tVNS on depressive symptoms measured by the Hamilton Depressive Rating Scale version 17 items (HDRS-17) in patients with moderate / severe depressive episode.

次要结局

未报告次要终点

研究者

发起方
Santa Casa Medical School
申办方类型
Other
责任方
Principal Investigator
主要研究者

Pedro Shiozawa

Coordinator - Interdisciplinary Center for Clinical Neuromodulation

Santa Casa Medical School

相似试验